Pfizer Share Price Today

Florida Attorney General sues Pfizer over alleged misleading vaccine ads

Florida Attorney General James Uthmeier filed a lawsuit against Pfizer. The complaint alleges misleading advertising of the COVID-19 vaccine. CEO Dr. Albert Bourla is named as a defendant in the suit.

Pfizer receives ₹1.26 crore income tax penalty for AY 2023-24

Pfizer Limited received a penalty of ₹1.26 crore from the Income Tax Transfer Pricing authority. The penalty relates to alleged non-furnishing of information during the AY 2023-24 audit. Company states the order has no material impact on financials and operations. Pfizer plans to appeal the order issued under Section 271G of the Income Tax Act.

Pfizer Q2FY26 Results: Revenue tops estimates, guidance raised by $500 million

Pfizer reported Q2 2026 revenues of $50 billion, exceeding expectations, with 1% operational YoY growth and 5% operational growth excluding COVID products. Adjusted diluted EPS was $0.77, beating expectations; reported loss per share was -$0.04 due to a $4.3 billion non-cash intangible asset impairment for SV. Full-year 2026 revenue guidance raised by $500 million at the midpoint to $60.5 billion to $62.5 billion; adjusted diluted EPS guidance reaffirmed at $2.80 to $3.00. Launch and acquired products delivered $3.2 billion in revenue, growing 18% operationally, or 27% excluding one-time items from Q2 2025. Total net cost savings from expanded programs now expected to reach approximately $9.7 billion through 2029.

Pfizer India’s Sharad Goswami resigns as Senior Director

Sharad Goswami resigns as Senior Director – Policy & Public Affairs at Pfizer Limited. Cessation from Senior Management Personnel status effective September 25, 2026. Departure disclosed under Regulation 30 of SEBI LODR Regulations, 2015. Reason cited is pursuit of opportunities outside the company.

NCCN awards grants for metastatic prostate cancer quality initiatives

NCCN ORP awards grants for four mPCA quality improvement projects. Funding and oversight provided by Pfizer Global Medical Grants. Projects target biomarker testing, polypharmacy reduction, and care standardization. Selected researchers include experts from UT Southwestern, Georgetown, Northwestern, and Moffitt. Initiatives aim to close treatment gaps and increase clinical trial access.

Pfizer discontinues Minipress XL sales, to receive $13.9 million

Pfizer Limited discontinues Minipress XL sales effective September 7, 2026. Decision follows Pfizer Inc. USA halting manufacture of the product. Company to receive $13.9 million (~₹131.38 crore) lump sum payment. Transaction approved by Board of Directors in meeting on September 7, 2026.